Real-world experience with teplizumab in stage 2 type 1 diabetes: a plain language summary

Area of Science:

• Immunology
• Endocrinology
• Clinical Research

Background:

• Teplizumab is approved to delay clinical diagnosis of stage 3 type 1 diabetes (T1D) in individuals with stage 2 T1D.
• Real-world patient and caregiver experiences with teplizumab treatment are not well-documented.

Purpose of the Study:

• To survey adults and caregivers of children treated with teplizumab for early T1D regarding their experiences and views.
• To gather insights on patient perspectives on T1D screening, diagnosis, and teplizumab treatment.

Main Methods:

• A survey was administered to adults treated with teplizumab and caregivers of children treated with teplizumab for early T1D.
• The survey collected data on respondent characteristics, T1D diagnosis experiences, and feelings about teplizumab treatment and future health expectations.

Main Results:

• Most participants were grateful for the opportunity to receive teplizumab and believed it would simplify T1D management.
• Despite concerns about disease progression and close glucose monitoring, participants would recommend teplizumab and make the same treatment decision again.
• The survey is the first to explore real-world experiences with teplizumab in early T1D outside of clinical trials.

Conclusions:

• This survey provides valuable insights into the lived experiences of individuals undergoing teplizumab treatment for early T1D.
• Findings can inform patients considering T1D screening or teplizumab, and clinicians evaluating treatment options.